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Limited data address the impact of HIV coinfection on the pharmacokinetics (PK) of antituberculosis drugs in sub-Saharan Af-
rica. A total of 47Malawian adults underwent rich pharmacokinetic sampling at 0, 0.5, 1, 2, 3, 4, 6, 8, and 24 h postdose. Of the
subjects, 51%were male, their mean age was 34 years, and 65%were HIV-positive with a mean CD4 count of 268 cells/l. Anti-
tuberculosis drugs were administered as fixed-dose combinations (150 mg rifampin, 75 mg isoniazid, 400 mg pyrazinamide, and
275 mg ethambutol) according to recommended weight bands. Plasma drug concentrations were determined by high-perfor-
mance liquid chromatography (rifampin and pyrazinamide) or liquid chromatography-mass spectrometry (isoniazid and
ethambutol). Data were analyzed by noncompartmental methods and analysis of variance of log-transformed summary parame-
ters. The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of
drug in plasma (Cmax) of 4.129g/ml (2.474 to 5.596g/ml), area under the curve from 0 to 24 h (AUC0–) of 21.32g/ml · h
(13.57 to 28.60g/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97g/ml (2.979 to 4.544g/ml),
AUC0–24 of 22.5 (14.75 to 34.59g/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21g/ml (30.00 to
41.60g/ml), AUC0–24 of 386.6g/ml · h (320.0 to 463.7g/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol,
Cmax of 2.278g/ml (1.694 to 3.098g/ml), AUC0–24 of 20.41g/ml · h (16.18 to 26.27g/ml · h), and half-life of 7.507 (6.517 to
8.696 h). The isoniazid PK data analysis suggested that around two-thirds of the participants were slow acetylators. Dose, weight,
and weight-adjusted dose were not significant predictors of PK exposure, probably due to weight-banded dosing. In this first
pharmacokinetic study of antituberculosis drugs inMalawian adults, measures of pharmacokinetic exposure were comparable
with those of other studies for all first-line drugs except for rifampin, for which the Cmax and AUC0–24 values were notably lower.
Contrary to some earlier observations, HIV status did not significantly affect the AUC of any of the drugs. Increasing the dose of
rifampinmight be beneficial in African adults, irrespective of HIV status. Current co-trimoxazole prophylaxis was associated
with an increase in the half-life of isoniazid of 41% (P 0.022). Possible competitive interactions between isoniazid and sulfa-
methoxazole mediated by theN-acetyltransferase pathway should therefore be explored further.
Tuberculosis (TB) and HIV coinfection remains a challengingpublic health problem in sub-Saharan Africa. TB is the most
common serious opportunistic infection in people living with
HIV/AIDS, while a majority of individuals with TB are HIV sero-
positive. Treatment guidelines for TB do not recommend any ad-
justments in TB treatment in the presence of HIV coinfection,
unless protease inhibitors are also being administered. Although a
recent systematic review concluded that a longer duration of rifa-
mycin-based treatment reduces the recurrence rates of TB after
treatment in HIV-positive people, this appeared not to be true
when antiretroviral therapy (ART) was coadministered (1). Con-
cern has nonetheless lingered as to the reliability of TB treatment
in this context, with repeated reports of lower plasma concentra-
tions of antituberculosis drugs, particularly rifampin, in HIV-
coinfected TB patients (2–11) and the association of these findings
with worse treatment outcomes in some studies (11, 12).
Due to their logistical complexity, however, few intensive
pharmacokinetic (PK) studies of HIV-infected tuberculosis pa-
tients have been performed in the sub-Saharan region, with the
bulk of the published data originating from South Africa (7, 9, 10,
13). Consequently, larger and more detailed field PK studies are
required in order to obtain accurate estimates of key PK and phar-
macodynamics parameters, define the full extent of the interindi-
vidual variability in PK, and evaluate the impact of important
covariates such as HIV coinfection and coadministration of anti-
retroviral therapy. Such studies may also assist in determining the
possible impact of local treatment practices, drug formulation,
nutritional factors, and pharmacogenetic differences on PK pa-
rameters in these different settings.
In Malawi, the HIV infection prevalence in adults is around
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11%, and 70% of TB patients are HIV infected. HIV infection and
TB treatment are provided according to a public health approach,
using standardized combination regimens with generic drugs,
which are provided free of charge in both programs. The TB treat-
ment is provided through a well-established community directly
observed treatment (DOT) system. Infrastructure to support
therapeutic drug monitoring of TB drugs and PK data for antitu-
berculosis drugs in Malawian adults are not available. The
National TB Programme expressed a need to address concerns
about the pharmacological robustness of TB treatment in the local
context with the high rates of HIV coinfection and malnutrition.
We therefore determined the PK profiles of the four drugs com-
prising the first-line TB treatment regimen in a representative co-
hort of Malawian TB patients to establish whether they attain op-
timal plasma TB drug concentrations and whether HIV status and
other variables have an important impact on pharmacokinetics.
MATERIALS AND METHODS
Clinical protocol. The study took place at outpatient clinics and tubercu-
losis wards of Queen Elizabeth Central Hospital, a tertiary government
hospital with around 1,000 beds in Blantyre, Malawi. Malawian adults
(16 years) who had a diagnosis of sputum microscopy acid-fast bacilli-
positive pulmonary TB and who provided informed consent were en-
rolled in a pharmacokinetic study from January 2007 to February 2008.
Sampling took place after a minimum of 2 weeks of TB treatment and
before the end of the intensive treatment phase. Patients were eligible for
enrollment irrespective of their current antiretroviral therapy (ART) for
HIV infection. Patients with an unknown HIV status were encouraged to
undergo HIV testing. Patients who were unwilling to be tested or have the
result disclosed to the study team were excluded from the study. Other
exclusion criteria were hemoglobin (Hb) of8 g/dl, vomiting within the
preceding 72 h, diarrhea more than 3 times per day during the preceding
3 days, and discontinuation of ART within the last 2 weeks.
We obtained demographic and clinical information, including gen-
der, age, height, weight, HIV status, concomitant drug use, and ART du-
ration. Following the WHO criteria, malnutrition was defined as a body
mass index (BMI) of18.5 kg/m2. We collected a venous sample for the
CD4 count and concentrations of creatinine, Hb, and alanine amino-
transferase (ALT). HIV status was determined by rapid tests using HIV
Determine (Invernos Med, Japan Co. Ltd.) and confirmed by a second
assay with Uni-Gold (Trinity Biotech PK, Ireland), according to the na-
tional protocol at the time.
Antituberculosis drugs were administered as fixed-dose combination
(FDC) tablets, approved by the National TB Programme and the WHO
and dosed according to the recommended weight bands. Each tablet con-
tained 150 mg rifampin, 75 mg isoniazid, 400 mg pyrazinamide, and 275
mg ethambutol. Doses were administered orally once daily within the
following body weight bands: 25 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets;
55 to 74 kg, 4 tablets; and75 kg, 5 tablets.
Ethical approval of the study protocol was obtained from the National
Health Sciences Research Committee.
Bioanalytical methods. Rich pharmacokinetic sampling took place
during the intensive phase of the antituberculosis therapy. The first sam-
ple was taken at 0 h (predose), after which the patient had a light breakfast
and then took the TB drugs. Dosing was performed under observation by
the research nurse. An intravenous cannula was inserted and maintained
using heparin-saline flushes. Samples were then drawn at 0.5, 1, 2, 3, 4, 6,
8, and 24 h postdose and were immediately transported in a closed cooler
box to the Malawi-Liverpool Wellcome Trust Clinical Research labora-
tory on the hospital premises, spun down, and snap-frozen at80°C until
transportation on dry ice to Liverpool, United Kingdom.
The rifampin and pyrazinamide plasma concentrations were deter-
mined using high-performance liquid chromatography on a Shimadzu
LC 2010 HT system (Shimadzu, Manchester, United Kingdom). The iso-
niazid and ethambutol concentrations were determined simultaneously
using liquid chromatography-tandem mass spectrometry (LC-MS/MS)
on a triple-quadrupole TSQ Quantum Access mass spectrometer
(Thermo Scientific, Hemel Hempstead, United Kingdom). All methods
incorporated appropriate internal standards (13) and were validated to
internationally recognized acceptance criteria (14). The lower limits of
quantification for the assays were 0.5 g/ml, 2.5 g/ml, 20 ng/ml, and 10
ng/ml for rifampin, pyrazinamide, isoniazid, and ethambutol, respec-
tively (13).
Statistical methods. Noncompartmental PK analysis of plasma con-
centration-time data was performed with Kinetica 4.1.1 (Adept Scientific
Ltd., Armor Way, Letchworth Garden City, United Kingdom) using the
trapezoidal rule with the log up-linear down option and manual adjust-
ment of the range of included time points. Data summaries, graphics, and
analysis of variance of the summary PK parameters were performed in R
2.14.1 (R Foundation for Statistical Computing, Vienna, Austria). Anal-
ysis of variance was performed with log-transformed PK parameters
where appropriate and model assumptions were checked using routine
graphical diagnostics. Generalized additive models were used to evaluate
continuous covariate relationships using the package mgcV, and cluster-
ing analysis for subpopulation detection in the parameter distributions
was performed using the package mclust.
RESULTS
Forty-seven patients were enrolled (Table 1). The mean age was 34
years, and 24 (51%) were male. Thirty (65%) were HIV-positive
with a mean CD4 count of 268 cells/l. Thirteen were receiving
nevirapine-based and one was receiving efavirenz-based antiret-
roviral therapy. All HIV-positive participants received co-tri-
moxazole prophylaxis, and none had chronic diarrhea. The mean
weight-adjusted dose received for each of the drugs was 10.03
mg/kg for rifampin, 5.01 mg/kg for pyrazinamide, 26.58 mg/kg for
isoniazid, and 18.38 mg/kg for ethambutol. Plasma concentration
curves for each of the drugs are shown in Fig. 1. The summary PK
parameters derived from the noncompartmental analysis are pre-
sented in Table 2. The PK parameters for rifampin, isoniazid, pyr-
azinamide, and ethambutol could be computed for 41, 46, 46, and
47 participants, respectively, due to missing observations or a
noncredible PK profile in some participants. Estimates of the ap-
parent terminal elimination half-life (z) were based on at least
three data points in all cases with a mean number of data points of
3.4, 3.9, 3.9, and 3.68 contributing to the analysis and a percent
TABLE 1 Patient characteristics (n  47)
Characteristic Valuea
Age (yr) 34.4 (16–60)
Male sex 24 (52)
Weight (kg) 52.52 (35.80–74.30)
Height (m) 1.65 (1.51–1.81)
BMI (kg/m2) 19.29 (13.92–28.39)
Malnutrition (BMI18.5 kg/m2) 19 (40)
TB retreatment regimen 6 (13)
HIV status 30 (65)
WHO stage 4 6 (13)
CD4 count (cells/l) 268 (3–1,204)
Co-trimoxazole prophylaxis 19 (40)
Nevirapine-based ART 12 (26)
Efavirenz-based ART 1 (2)
Hb (g/dl) 11.39 (8.50–19.20)
Creatinine (mg/dl) 0.8 (0.4–1.9)
ALT (U/liter) 15.7 (5–44)
a Values are means (ranges) or no. (%).
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extrapolation to infinity on the area under the curve (AUC0 –) of
13.49, 5.31, 28.10, and 14.80 for the four drugs, respectively.
For rifampin, the median observed maximum concentration
of drug in plasma (Cmax) was 4.13 g/ml (interquartile range
[IQR], 2.47 to 5.60 g/ml) and the AUC0 – was 21.32 g/ml · h
(IQR, 13.57 to 28.60g/ml · h). In 14 of 47 (30%) participants, the
Cmax occurred at 4 h postdosing or later, representing delayed
absorption, and in 4 of these cases the noncompartmental analysis
failed to produce a meaningful estimate of the AUC. TheCmax and
AUC0 –24 were not significantly associated with a weight-adjusted
dose (P 0.10 and 0.06), while the AUC0 – was negatively corre-
lated with an absolute dose (P  0.048). On closer examination,
this finding appeared to be driven by exposure in participants with
the lowest body mass. As expected, both measures of volume of
distribution (apparent volume of distribution during terminal
phase [Vz/F] and volume of distribution at steady state [Vss/F])
tended to scale positively with both linear and power functions of
weight (P 0.08 and 0.09).
For isoniazid, the median observed Cmax was 3.97g/ml (IQR,
2.98 to 4.54 g/ml) and the AUC0 – was 22.5 g/ml · h (IQR,
14.75 to 34.59 g/ml · h). No relationship was observed between
these parameters and the absolute or weight-adjusted dose. The
FIG1 Semilogarithmic plots of the plasma concentrations of the four first-line drugs. The solid lines show the median concentrations, and the dashed lines show
the upper and lower quartiles.
TABLE 2 Summary of pharmacokinetic parameters derived from noncompartmental analysis
Parametera
Results (median [interquartile range]) for:
Rifampin (n 41) Isoniazid (n 46) Pyrazinamide (n 46) Ethambutol (n 47)
Cmax (g/ml) 4.13 (2.47–5.60) 3.970 (2.979–4.544) 34.21 (30.00–41.60) 2.278 (1.694–3.10)
Tmax (h) 3.00 (2.00–4.00) 2.00 (1.00–3.00) 2.00 (1.00–3.00) 3.00 (2.00–4.00)
AUC0-last (g/ml · h) 16.62 (11.97–24.28) 21.83 (13.80–33.89) 273.10 (173.7–388.5) 16.72 (12.72–22.93)
AUC0- (g/ml · h) 21.32 (13.57–28.60) 22.50 (14.75–34.59) 386.6 (320.0–463.7) 20.41 (16.18–26.27)
t1/2(h) 2.45 (1.86–3.08) 3.93 (3.18–4.73) 6.821 (5.71–8.04) 7.507 (6.517–8.69)
CL/F (liters/h) 25.11 (16.62–39.41) 11.60 (7.179–18.42) 3.577 (2.66–4.75) 48.39 (34.31–62.73)
Vz/F (liters) 83.96 (67.21–113.70) 66.67 (48.25–92.37) 35.03 (28.24–43.51) 488.40 (376.80–630.70)
Vss/F (liters) 130.20 (90.75–202.40) 72.35 (59.56–98.33) 38.74 (31.44–46.13) 498.90 (410.60–722.80)
a Abbreviations: Cmax, observed maximum concentration of drug in plasma; Tmax, time to maximum concentration of drug in plasma; AUC0 –last, area under the curve to last
observed plasma concentration; AUC0 –, area under the curve extrapolated to infinity; t1/2, apparent elimination half-life; CL/F, apparent clearance; Vz/F, volume of distribution;
Vss/F, volume of distribution at steady state.
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median apparent terminal elimination half-life of isoniazid was
3.93 h (IQR, 3.18 to 4.73 h). Seven of 46 (15%) had a half-life
of 130 min, suggesting that 84.8% of participants would con-
ventionally be classified as the slow acetylator phenotype. How-
ever, since the semilogarithmic plot of the data suggested possible
biphasic elimination with 38 of 46 participants (83%) showing
detectable concentrations of isoniazid at 24 h, these parameters
were reestimated with this data point omitted. The median elim-
ination half-life was then 2.83 h (IQR, 2.010 to 3.729 h) with 67%
classified as slow acetylators. These predictions of the proportion
of slow acetylators were supported by finite normal mixture mod-
els of the distribution of the half-lives. For the data set with the
24-h data point excluded, the algorithm predicted two subpopu-
lations with estimated mean half-lives of 1.84 and 3.64 h, compris-
ing 36% (fast/intermediate acetylators) and 64% (slow acetyla-
tors) of the participants, respectively. A three-component mixture
model did not convincingly discriminate between fast and inter-
mediate acetylators. Similarly to the results for rifampin, Vz/F and
Vss/F tended to scale with a linear or power function of body mass
(P 0.102 and 0.053). Concomitant co-trimoxazole prophylaxis
was associated with an increase in the half-life of isoniazid of 41%
(P 0.022).
For pyrazinamide, the median observed Cmax was 34.21g/ml
(IQR, 30.00 to 41.60 g/ml) and the AUC0 – was 386.6 g/ml · h
(320.0 to 463.7 g/ml · h). There was no consistent relationship
between these parameters and the absolute or weight-adjusted
dose. The Cmax was reduced by 15% in HIV-positive participants,
although neither the AUClast nor AUC0 – was affected. Vz/F in-
creased by 0.42 liters for each additional kilogram of body weight
(P 0.001), and this relationship accounted for an apparent uni-
variate effect of sex on this parameter in multivariate analysis.
For ethambutol, the median observed Cmax was 2.278 g/ml
(IQR, 1.694 to 3.098 g/ml) and the AUC0 – was 20.41 g/ml · h
(IQR, 16.18 to 26.27 g/ml · h). There was no observed relation-
ship between these parameters and the absolute or weight-ad-
justed dose. Vz/F increased by 5.18 liters for each additional kilo-
gram of body weight (P 0.009), and this relationship accounted
for an apparent univariate effect of sex on this parameter in mul-
tivariate analysis. Neither serum creatinine nor the glomerular
filtration rate was related to the elimination half-life.
With the exception of the Cmax of pyrazinamide, HIV coinfec-
tion did not significantly affect the PK parameters of any of the
drugs studied. Age, gender, and antiretroviral therapy also had no
effect (data not shown).
DISCUSSION
Since the early reports of altered plasma concentrations of antitu-
berculosis drugs in HIV-positive patients, debate has continued as
to the contribution of HIV coinfection to interpatient PK variabil-
ity in the treatment of TB. While sub-Saharan Africa bears the
brunt of HIV-associated tuberculosis and an increasing incidence
of multidrug resistance, surprisingly few PK studies have been
performed in the region and fewer still have been able to employ
intensive blood sampling. Although logistically simpler, sparse
sampling can systematically underestimate key measures of expo-
sure such as the Cmax and AUC and may not correctly define the
characteristics of the elimination phase. Our comparatively inten-
sive sampling allowed for parameter estimates with higher preci-
sion and less truncation of the AUC than some earlier studies. The
values of the parameters from this first PK study of antitubercu-
lous drugs in Malawian adults are broadly comparable with data
from two sites in South Africa (7, 10), one site from Tanzania (15),
and one from Botswana (8), although some differences are worthy
of comment.
Contrary to some earlier observations (3, 4, 6), HIV infection
did not significantly or consistently affect the pharmacokinetics of
any of the four first-line antituberculosis drugs. The only excep-
tion was a small reduction in the Cmax of pyrazinamide, which did
not affect the overall plasma exposure as measured by the AUC.
These findings are reassuring and in accordance with other re-
search supporting similar efficacy of TB treatment in HIV-posi-
tive patients (16). Early studies focused on patients with advanced
HIV disease and associated diarrhea prior to the introduction of
highly active antiretroviral therapy. About half of the HIV-posi-
tive participants in our study were receiving ART according to
national program guidelines, and all were receiving co-trimoxa-
zole prophylaxis, which may have resulted in less advanced immu-
nosuppression and fewer associated opportunistic infections.
However, 50% had a CD4 level of200 cells/mm3 with a median
body mass of only 45 kg, 12 kg less than those whose CD4 counts
were200 cells/mm3. The cohort was thus representative of Ma-
lawian patients with HIV-TB coinfection in whom late presenta-
tion and advanced immunosuppression remain commonplace.
Thirty percent of subjects exhibited delayed absorption of ri-
fampin defined as a time to maximum concentration of drug in
plasma (Tmax) of 4 h. While this phenomenon has been de-
scribed previously (17), it also has practical consequences for
sparse PK sampling strategies, which may produce falsely low or
no estimates of AUC for these participants. This may be one rea-
son why the PK parameters of rifampin have been reported as low
in many studies. However, despite the intensive sampling used in
our study, rifampin was the drug for which the AUC was lowest by
comparison with other studies from the region. Although the PK-
pharmacodynamic targets in TB are not currently widely agreed
upon, with use of published sensitivity data (18), the median
AUC/MIC achieved by patients in this study would be 85.3, which
appears to be less than optimal on the basis of in vivo and human
data (12, 19). Our findings therefore add support to the rationale
for ongoing clinical trials in which higher doses of rifampin for
treatment of tuberculosis are being evaluated.
Although the relationships expected between the measures of
volume of distribution and body mass could be estimated in this
data set, we did not find any clear relationship between the weight-
adjusted dose and either the Cmax or the AUC. This is reassuring
and perhaps not surprising due to the weight-banded approach to
dosing that is now commonly used for antituberculosis drugs and
that is designed to achieve a narrow range of exposures irrespec-
tive of body weight. A larger and similarly intensive pharmacoki-
netic study in South Africa in which most patients received singly
formulated drugs from different manufacturers rather than fixed-
dose combinations reported that the weight-adjusted dose was a
predictor of the AUC for all the first-line drugs (7). However, a
second study using a high-quality weight-banded fixed quadru-
ple-drug combination found that the weight-adjusted dose was a
significant predictor of the AUC only for pyrazinamide and that
there was an independent residual positive relationship with body
mass alone (10). Other studies from the region used both singly
formulated drugs and FDC tablets but did not present a detailed
analysis of these covariates, so it remains unclear whether these
findings relate to differences in formulation and dosing or to col-
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linearity among the dose and weight variables in the existing data
sets.
Due to the intensive sampling and sensitive bioanalytical
method, it was possible to clearly demonstrate the biphasic elim-
ination kinetics of isoniazid. This has been noted in some popu-
lation PK studies (20) but is often not accounted for in noncom-
partmental analyses of sparse data and can result in inaccurate
estimation of the terminal half-life and parameters derived from
it. With use of a reduced data set, a distribution of half-lives and
predicted acetylator phenotypes was observed that is similar to
findings with other Central African populations, whether by an
arbitrary cutoff or empirical clustering (21, 22). Of note, the pro-
portion of slow acetylators was much higher in our study and that
of Tostmann et al. (15) than in studies in the Western Cape (7, 23),
emphasizing the need for more complete characterization of iso-
niazid PK and the diversity of the NAT2 genotype across the re-
gion.
The finding of a possible interaction between isoniazid and
trimethoprim-sulfamethoxazole was unexpected and should be
explored further. This might be a chance finding that is difficult to
dissociate from the effect of HIV coinfection itself in our data set,
but the N-acetylation pathway is known to be one of the primary
routes of elimination of sulfamethoxazole (24) and is therefore a
plausible target for competitive interactions with isoniazid.
In conclusion, in this first intensive PK study of first-line anti-
tuberculosis drugs in adult Malawians, HIV coinfection had no
clinically significant effect on the key PK parameters that may be
related to efficacy, supporting the current recommendations for
use of similar regimens for HIV-positive and -negative individu-
als. Given the low exposure to rifampin, increasing its dose could
be beneficial in African adults, irrespective of HIV status.
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